Table 1.

Guideline scope^*

Medications		Vaccines†		Rheumatic and musculoskeletal disorders
Immunosuppressive	Nonimmunosuppressive	Non–live attenuated	Live attenuated
Glucocorticoids  Prednisone  Methylprednisolone  Dexamethasone  Hydrocortisone csDMARDs  Methotrexate  Leflunomide  Azathioprine  Mycophenolate mofetil/mycophenolic acid  Calcineurin inhibitors (cyclosporine, tacrolimus, voclosporin)  Cyclophosphamide bDMARDs  TNF inhibitors (etanercept, adalimumab, certolizumab, golimumab, infliximab)  IL‐6R inhibitors (tocilizumab, sarilumab)  IL‐17 inhibitors (secukinumab, ixekizumab)  IL‐12/23 inhibitors (ustekinumab)  IL‐23 inhibitors (guselkumab, tildrakizumab, risankizumab)  IL‐1 inhibitors (anakinra, canakinumab, rilonacept)  T cell costimulation inhibitor (CTLA4‐Ig/abatacept)  B cell–depleting agents (rituximab, ocrelizumab, obinutuzumab)  BLyS/BAFF inhibitors (belimumab, tabalumab)  Interferon‐α receptor inhibitor (anifrolumab) tsDMARDs  JAK inhibitors (tofacitinib, baricitinib, upadacitinib, filgotinib, ruxolitinib)	Hydroxychloroquine Sulfasalazine Colchicine Apremilast Denosumab IVIG	Seasonal influenza  Standard dose, high dose, adjuvanted Pneumococcal  PPSV23, PCV13‡ Other  Hemophilus influenza  Hepatitis A  Hepatitis B  Human papillomavirus  Inactivated polio  Meningococcus B  Meningococcus ACWY  Tetanus toxoid/Td/Tdap  Typhoid (injectable)  Zoster subunit	Influenza (intranasal) MMR Rotavirus Typhoid (oral) Varicella Yellow fever Zoster	Inflammatory arthropathies  Rheumatoid arthritis  Psoriatic arthritis  Ankylosing spondylitis  Spondyloarthritis  Enthesitis‐related arthritis  IBD‐associated arthritis  Juvenile idiopathic arthritis Connective tissue diseases  Systemic lupus erythematosus  Sjögren’s syndrome  Systemic sclerosis  Idiopathic inflammatory myopathies  Mixed connective tissue disease  Undifferentiated connective tissue disease  Antiphospholipid antibody syndrome Vasculitides  Granulomatosis with polyangiitis  Microscopic polyangiitis  Eosinophilic granulomatosis with polyangiitis  Giant cell arteritis  Polyarteritis nodosa  Takayasu arteritis  Cryoglobulinemic vasculitis  Relapsing polychondritis  Behçet’s disease  Kawasaki disease  IgA vasculitis (Henoch‐Schönlein)  Primary CNS vasculitis  Goodpasture’s syndrome (anti‐GBM)  Cogan’s syndrome  Cutaneous small vessel vasculitis  Rheumatoid vasculitis  Urticarial vasculitis Other inflammatory disorders  Sarcoidosis  Adult‐onset Still’s disease  Polymyalgia rheumatica  Gout  Pseudogout  IgG4‐related disease  Autoinflammatory disorders

^*MMR = measles, mumps, and rubella (vaccine); PPSV23 = pneumococcal polysaccharide vaccine; PCV13 = pneumococcal conjugate vaccine; csDMARDs = conventional synthetic disease-modifying antirheumatic drugs; IVIG = intravenous immunoglobulin; IBD = inflammatory bowel disease; bDMARDs = biologic DMARDs; TNF = tumor necrosis factor; IL-6R = interleukin-6 receptor; BLyS = B lymphocyte stimulator; tsDMARDs = targeted synthetic DMARDs; CNS = central nervous system; anti-GBM = anti–glomerular basement membrane (disease).

^†COVID-19 vaccines were not included in this guideline because of the fast-changing face of the pandemic and related literature.

^‡The recently approved pneumococcal vaccines, PCV15 and PCV20, were not included in the evidence review but are discussed in the text with reference to current Centers for Disease Control and Prevention guidelines.